PubMed Health⌕ Search

Biomedical subjects

S G Hulst

Publications and source records attributed to S G Hulst.

14 recordsLinked to original sources
PubMed1980

Two patients with recurrent pneumonias in one lung.

Case histories are described of two young patients, both known to have recurrent infections of one pulmonary lobe. Further investigations (especially aortography) disclosed the cause in both to be an intrapulmonary sequestration. Surgical intervention made both patients symptom-free. The aetiology, clinical and investigational findings as well as therapy are discussed. The need for further investigations in patients with recurring infections of one pulmonary lobe is stressed.

Adolescent↗
PubMed1976

Treatment of insulin-induced lipoatrophy.

Twenty children with insulin-induced lipoatrophy were successfully treated by injecting the insulin into the lipoatrophic area. In 10 children insulin therapy was replaced by monocomponent insulins, while the other 10 children were treated with the insulins they previously used. It is concluded that both monocomponent and less purified insulins are suitable for treating the complication of insulin therapy when the insulin is injected into the lipoatrophic area.

Adipose Tissue↗
PubMedDate not supplied

Time-action profile of zinc human insulin (recombinant DNA) in young volunteers as compared with zinc porcine insulin (Monotard).

Zinc human insulin (recombinant DNA) or zinc PPI (Monotard) 20 U was injected subcutaneously to study the time-action profile in six healthy volunteers. During the test period they received a 10-g biscuit containing 3% moisture, 7% protein, 10% fat, 80% carbohydrate, and 30 ml of water every hour. The onset of action with zinc human insulin occurred earlier than with zinc PPI. Also, the intensity of the blood sugar-lowering effect was more pronounced 3 and 4 h after administration of insulin. No other statistically significant differences were detected between the two blood glucose curves. The results show that it is possible to develop a zinc human insulin formulation with a duration of the blood sugar-lowering effect equal to a zinc PPI formulation.

Adult↗